The first China International Supply Chain Promotion Expo opened in Beijing on November 28th. Novo Nordisk showcased the three major chains of "R&D chain, manufacturing chain, and health chain" and their cooperation ecology at the Chain Expo, showcasing the company's innovative cooperation achievements in various aspects of R&D, production, and operation over the years.
At the research and development level, Novo Nordisk China R&D Center relies on the INNOVO open innovation platform to build a new ecosystem of pharmaceutical open innovation cooperation. On the production level, Novo Nordisk Tianjin production plant has been continuously increasing capital and expanding production for many years, driving the coordinated development of upstream and downstream while meeting the medication needs of patients. At the operational level, the "China Tongchuang" project aims to promote synchronous clinical practice between China and the world. As of now, Novo Nordisk has established clinical research strategic cooperation centers with 15 hospitals and 30 professional departments to strengthen academic exchanges with Chinese hospitals.
"Health chain" is the highlight of Novo Nordisk's exhibition this time. It shows the company's life-cycle chronic disease management chain covering all links of "prevention, screening, diagnosis and treatment, management" in the field of diabetes, rare diseases and obesity. Among them, the world's first basic insulin GLP -1RA injection Novotech was included in the national medical insurance catalog at the beginning of this year. In addition, Novo Nordisk's recently released one-stop intelligent diabetes self-management solution - Novo Nordisk Care Mobile Application Software (APP) also appeared at the booth.
Novo Nordisk has also established a sustainable development zone to share the significant achievements of the company's first three-year plan for zero pollution recycling. "Circular zero pollution" is a global environmental strategy proposed by Novo Nordisk in 2019, aiming to achieve carbon neutrality in various business areas of the company by 2030.
During the Chain Expo, Novo Nordisk announced the deepening of cooperation with China National Pharmaceutical Group Pharmaceutical Logistics Co., Ltd., further expanding and improving warehousing and distribution facilities and equipment, and optimizing the supply chain network layout.
Zhou Xiaping, Senior Vice President of Novo Nordisk Global and President of Greater China, said, "Novo Nordisk hopes to expand its circle of friends through this participation in the Chain Expo, work together with all parties to drive change, and better serve Chinese patients. Novo Nordisk will continue to fully fulfill its commitment to 'in China, for China; in China, for the world', continuously deepen its layout, and participate more deeply in the global research and development chain, manufacturing chain, and health chain."